Skip to main content
Premium Trial:

Request an Annual Quote

Takeda Extends Gene Logic Database Subscription

NEW YORK, February 18 - Takeda has extended its subscription to Gene Logic's GeneExpress database and tools, Gene Logic said today.


The agreement expands Takeda's access to Gene Logic's BioExpress dataset, which it accesses along with the company's ToxExpress system and its GeneExpress expression database under a multi-year agreement it signed last March.


Financial terms of the deal, completed in collaboration with Amersham Biosciences KK, Gene Logic's sales and marketing partner in Japan, were not disclosed.

BioExpress includes genomic and clinical data derived from a variety of normal and diseased human tissues, tissues from model animal systems, and human and animal cell lines. ToxExpress is a database containing
expression profiles from organs affected by toxicity and the results of rat and human cell samples treated with various compounds. Gene Logic claims ToxExpress can predict what compounds may cause liver toxicity. GeneExpress was designed to help researchers mine, analyze, index, and visualize data.


Takeda, a Japanese drug and vitamin powerhouse, has annual sales topping $7 billion.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.